BMO Capital analyst Jim Birchenough weighed in on Celgene (NASDAQ: CELG) following last night's news about the acquisition of Receptos ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE